
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated a steady increase in test processing for its EsoGuard product, with 2,841 tests completed in Q3, showcasing growth compared to previous quarters. The company's valuation reflects a balance between the inherent risks of early-stage commercialization and the substantial upside potential associated with its innovative products. Additionally, the anticipated significant growth in revenue from its various lines of business, particularly in the upcoming years, supports a strong outlook for the company.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million, indicating a deterioration compared to prior estimates and highlighting ongoing financial challenges within the company. The decline in EsoGuard test volumes—from 3,034 in Q1 to 2,756 in Q2—reflects decreasing demand and potential operational hurdles that could impede future revenue growth. Additionally, the company's reliance on early-stage products like Lucid and Veris, coupled with substantial risks related to product approval, commercialization, and market competition, further contributes to a negative outlook for PAVmed's stock.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares